-
EP2546233
European procedure
Extract from the Register of European Patents
EP About this file: EP2546233
| EP2546233 - HYDROBENZAMIDE DERIVATIVES AS INHIBITORS OF HSP90 [Right-click to bookmark this link] | |||
| Former [2013/03] | Hydrobenzamide derivatives as inhibitors of HSP90 | ||
| [2017/21] | Status | No opposition filed within time limit Status updated on 30.12.2018 Database last updated on 03.09.2024 | |
| Former | The patent has been granted Status updated on 19.01.2018 | ||
| Former | Grant of patent is intended Status updated on 12.01.2018 | ||
| Former | Examination is in progress Status updated on 15.12.2017 | ||
| Former | Grant of patent is intended Status updated on 14.05.2017 | ||
| Former | Examination is in progress Status updated on 07.11.2016 | Most recent event Tooltip | 30.12.2018 | No opposition filed within time limit | published on 30.01.2019 [2019/05] | Applicant(s) | For all designated states Astex Therapeutics Limited Milton Road Cambridge Cambridgeshire CB4 0QA / GB | [2013/03] | Inventor(s) | 01 /
Frederickson, Martyn 436 Cambridge Science Park Milton Road Cambridge, CB4 0QA / GB | 02 /
Lyons, John, Francis 436 Cambridge Science Park Milton Road Cambridge, CB4 0QA / GB | 03 /
Thompson, Neil, Thomas 436 Cambridge Science Park Milton Road Cambridge, CB4 0QA / GB | 04 /
Vinkovic, Mladen 436 Cambridge Science Park Milton Road Cambridge, CB4 0QA / GB | 05 /
Williams, Brian 436 Cambridge Science Park Milton Road Cambridge, CB4 0QA / GB | 06 /
Woodhead, Andrew, James 436 Cambridge Science Park Milton Road Cambridge, CB4 0QA / GB | 07 /
Woolford, Alison, Jo-Anne 436 Cambridge Science Park Milton Road Cambridge, CB4 0QA / GB | [2013/03] | Representative(s) | Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB | [N/P] |
| Former [2018/08] | Cooke, Richard Spencer Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB | ||
| Former [2013/03] | Cooke, Richard Spencer Elkington and Fife LLP Prospect House 8 Pembroke Road Sevenoaks, Kent TN13 1XR / GB | Application number, filing date | 12187611.4 | 12.10.2007 | [2013/03] | Priority number, date | GB20060020259 | 12.10.2006 Original published format: GB 0620259 | US20060829243P | 12.10.2006 Original published format: US 829243 P | [2013/03] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP2546233 | Date: | 16.01.2013 | Language: | EN | [2013/03] | Type: | B1 Patent specification | No.: | EP2546233 | Date: | 21.02.2018 | Language: | EN | [2018/08] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 30.11.2012 | Classification | IPC: | C07D209/44, C07C65/05, C07C69/02, A61P35/00, A61K31/496 | [2013/03] | CPC: |
A61P3/06 (EP);
C07D209/44 (EP,KR,NO,US);
C07C67/317 (US);
A61K31/496 (KR,NO);
A61P17/02 (EP);
A61P25/00 (EP);
A61P25/04 (EP);
A61P25/06 (EP);
A61P29/02 (EP);
A61P3/10 (EP);
A61P31/10 (EP);
A61P31/12 (EP);
A61P33/00 (EP);
A61P33/02 (EP);
A61P33/06 (EP);
A61P35/00 (EP);
A61P37/06 (EP);
A61P43/00 (EP);
A61P9/00 (EP);
A61P9/06 (EP);
A61P9/10 (EP);
A61P9/12 (EP);
C07C235/60 (EP,US);
C07C59/08 (EP,US);
C07C65/05 (KR,NO);
C07C67/313 (US);
C07C69/02 (NO);
C07C69/92 (EP,US)
(-)
| Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR [2018/08] |
| Former [2013/03] | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR | Extension states | AL | 05.07.2013 | BA | 05.07.2013 | HR | 05.07.2013 | MK | 05.07.2013 | RS | 05.07.2013 | Title | German: | Hydrobenzamidderivate als Hemmer von Hsp90 | [2017/23] | English: | HYDROBENZAMIDE DERIVATIVES AS INHIBITORS OF HSP90 | [2017/21] | French: | Dérivés d'hydrobenzamide en tant qu'inhibiteurs de hsp90 | [2017/23] |
| Former [2013/03] | Hydrobenzamidderivate als Hemmer von HSP90 | ||
| Former [2013/03] | Hydrobenzamide derivatives as inhibitors of HSP90 | ||
| Former [2013/03] | Dérivés d'hydrobenzamide en tant qu'inhibiteurs de HSP90 | Examination procedure | 05.07.2013 | Examination requested [2013/33] | 22.10.2013 | Amendment by applicant (claims and/or description) | 18.11.2013 | Despatch of a communication from the examining division (Time limit: M06) | 27.05.2014 | Reply to a communication from the examining division | 06.02.2015 | Despatch of a communication from the examining division (Time limit: M06) | 13.11.2015 | Reply to a communication from the examining division | 30.03.2016 | Despatch of a communication from the examining division (Time limit: M06) | 18.01.2017 | Reply to a communication from the examining division | 15.05.2017 | Communication of intention to grant the patent | 03.11.2017 | Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time | 05.12.2017 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 05.12.2017 | Fee for grant paid | 05.12.2017 | Fee for publishing/printing paid | 11.01.2018 | Information about intention to grant a patent | 11.01.2018 | Receipt of the translation of the claim(s) | Parent application(s) Tooltip | EP07824125.4 / EP2081895 | Opposition(s) | 22.11.2018 | No opposition filed within time limit [2019/05] | Request for further processing for: | The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent | 05.12.2017 | Request for further processing filed | 05.12.2017 | Full payment received (date of receipt of payment) Request granted | 15.12.2017 | Decision despatched | The application is deemed to be withdrawn due to failure to reply to the examination report | 18.01.2017 | Request for further processing filed | 18.01.2017 | Full payment received (date of receipt of payment) Request granted | 06.02.2017 | Decision despatched | The application is deemed to be withdrawn due to failure to reply to the examination report | 13.11.2015 | Request for further processing filed | 13.11.2015 | Full payment received (date of receipt of payment) Request granted | 25.11.2015 | Decision despatched | The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report | 22.10.2013 | Request for further processing filed | 22.10.2013 | Full payment received (date of receipt of payment) Request granted | 04.11.2013 | Decision despatched | Fees paid | Renewal fee | 08.10.2012 | Renewal fee patent year 03 | 08.10.2012 | Renewal fee patent year 04 | 08.10.2012 | Renewal fee patent year 05 | 08.10.2012 | Renewal fee patent year 06 | 14.10.2013 | Renewal fee patent year 07 | 14.10.2014 | Renewal fee patent year 08 | 12.10.2015 | Renewal fee patent year 09 | 11.10.2016 | Renewal fee patent year 10 | 11.10.2017 | Renewal fee patent year 11 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A]WO2006051808 (KYOWA HAKKO KOGYO KK [JP], et al) [A] 1-15 * compounds IA, IIA * * claim 1 *; | [A]WO2006055760 (SYNTA PHARMACEUTICALS CORP [US], et al) [A] 1-15 * page 5, line 13 - line 15 ** claim 1 *; | [AP]WO2006109085 (ASTEX THERAPEUTICS LTD [GB], et al) [AP] 1-15 * the whole document * | by applicant | US4666828 | US4683202 | US4801531 | US5192659 | US5272057 | US5882864 | US6218529 | - GRENERT, J BIOL CHEM., (1997), vol. 272, pages 23834 - 23850 | - KAMAL, NATURE, (2003), vol. 425, pages 407 - 410 | - BRAZIDEC, J. MED. CHEM., (2004), vol. 47, pages 3865 - 3873 | - JOLLY; MORIMOTO, JNCI, (2000), vol. 92, no. 19, pages 1564 - 1572 | - GIANNINI ET AL., MOL CELL BIOL., (2004), vol. 24, no. 13, pages 5667 - 76 | - ROE, CELL, (2004), vol. 116, pages 87 - 98 | - MATHEWS ET AL., ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, (2003), vol. 47, pages 2208 - 2216 | - COWEN; LINDQUIST, SCIENCE, (20050930), vol. 309, no. 5744, pages 2175 - 6 | - COWEN LE; LINDQUIST S., "Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi", SCIENCE, (20050930), vol. 309, no. 5744, pages 2185 - 9 | - DICKEY ET AL., CURR ALZHEIMER RES., (200504), vol. 2, no. 2, pages 231 - 8 | - PAREEK, T.K. ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (2006), vol. 103, pages 791 - 796 | - WANG; CHENG-HAUNG ET AL., ACTA PHARMACOLOGICA SINICA., (2005), vol. 26, pages 46 - 50 | - AMADORO, G, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (2006), vol. 103, pages 2892 - 2897 | - CHRISTOPH, T ET AL., NEUROPHARMACOLOGY, (2006), vol. 51, pages 12 - 17 | - RASHIDAN, J. ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (2005), vol. 102, pages 14080 - 14085 | - OSUGA, H. ET AL., PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, (2000), vol. 97, pages 10254 - 10259 | - WEISHAUPT, J. ET AL., MOLECULAR AND CELLULAR NEUROSCIENCE., (2003), vol. 24, pages 489 - 502 | - NAGKAGAWA, S; UMEHARA T; MATSUDA C ET AL., BIOCHEM. BIOPHYS. RES COMMUN., (2007), vol. 353, pages 882 - 888 | - WAXMAN L; WITNEY, M ET AL., PNAS, (2001), vol. 98, pages 13931 - 13935 | - BERGE ET AL., "Pharmaceutically Acceptable Salts", J. PHARM. SCI., (1977), vol. 66, pages 1 - 19 | - HANCOCK ET AL., J. PHARM. SCI., (1997), vol. 86, page 1 | - P. HEINRICH STAHL, CAMILLE G. WERMUTH, Pharmaceutical Salts: Properties, Selection, and Use, HARDCOVER, (200208), page 388 | - SHEEHAN ET AL., J. AMER. CHEM SOC., (1955), vol. 77, page 1067 | - SHEEHAN ET AL., J. ORG. CHEM., (1961), vol. 26, page 2525 | - CASTRO ET AL., TETRAHEDRON LETTERS, (1990), vol. 31, page 205 | - L. A. CARPINO, J. AMER. CHEM. SOC., (1993), vol. 115, page 4397 | - KONIG ET AL., CHEM. BER., vol. 103, no. 708, pages 2024 - 2034 | - TSUGAWA, ONCOLOGY 1993, (1993), vol. 50, page 418 | - GORRE, BLOOD, (2002), vol. 100, pages 3041 - 3044 | - BALI, CANCER RES., (2004), vol. 64, no. 10, pages 3645 - 52 | - BIGNELL, NATURE, (2002), vol. 417, no. 6892, pages 949 - 54 | - MITSIADES, BLOOD, (2006), vol. 107, pages 1092 - 1100 | - SITTLER, HUMAN MOLECULAR GENETICS, (2001), vol. 10, no. 12, pages 1307 - 1315 | - LANARO ET AL., HUMAN MOLECULAR GENETICS, (2001), vol. 10, no. 12, pages 1307 - 1315 | - YEO, BIOCHEM BIOPHYS RES COMMUN., (20031230), vol. 320, no. 3, pages 816 - 24 | - WAX, RHEUMATISM, (2003), vol. 48, no. 2, pages 541 - 550 | - RIGANO ET AL., ANN. N. Y. ACAD. SCI., (2007), vol. 1107, pages 1 - 10 | - SUN; LIAO, ARTERIOSCLER THROMB VASC BIOL., (2004), vol. 24, no. 12, pages 2238 - 44 | - STOELTZING, J NATL CANCER INST, (2004), vol. 96, pages 946 - 956 | - LIN, J CELL BIOCHEM., (20041201), vol. 94, no. 1, pages 194 - 201 | - KOBAYASHI, HYPERTENSION, (2004), vol. 44, no. 6, pages 956 - 62 | - YORGIN, J IMMUNOL., (19991215), vol. 164, no. 6, pages 2915 - 23 | - WHITNEY, PROC NATL ACAD SCI U S A., (20001220), vol. 98, no. 24, pages 13931 - 5 | - KAMAR, MALAR J., (20021215), vol. 2, no. 1, page 30 | - JAN, L.Y.; JAN, Y.N., "A Superfamily of Ion Channels", NATURE, (1990), vol. 345, no. 6277, page 672 | - SANGUINETTI, M.C.; JIANG, C.; CURRAN, M.E.; KEATING, M.T., "A Mechanistic Link Between an Inherited and an Acquired Cardiac Arrhythmia: HERG encodes the Ikr potassium channel", CELL, (1995), vol. 81, doi:doi:10.1016/0092-8674(95)90340-2, pages 299 - 307, XP002154291 DOI: http://dx.doi.org/10.1016/0092-8674(95)90340-2 | - TRUDEAU, M.C.; WARMKE, J.W.; GANETZKY, B.; ROBERTSON, G.A., "HERG, a Human Inward Rectifier in the Voltage-Gated Potassium Channel Family", SCIENCE, (1995), vol. 269, doi:doi:10.1126/science.7604285, pages 92 - 95, XP002926421 DOI: http://dx.doi.org/10.1126/science.7604285 | - R. G. STRICKLY, "Solubilizing Excipients in oral and injectable formulations", PHARMACEUTICAL RESEARCH, (2004), vol. 21, no. 2, pages 201 - 230 | - Remington's Pharmaceutical Sciences, MACK PUBLISHING COMPANY | - ANGERER, METH. ENZYMOL., (1987), vol. 152, page 649 | - "Fluorescence In Situ Hybridization: Technical Overview", JOHN M. S. BARTLETT, Molecular Diagnosis of Cancer, Methods and Protocols, 2nd ed.,, (200403), pages 077 - 088 | - DEPRIMO ET AL., BMC CANCER, (2003), vol. 3, page 3 | - JEZ, J.M. ET AL., CHEM BIOL., (200304), vol. 10, no. 4, pages 361 - 8 | - TURNBULL W.B.; DARANAS A.H., J. AM. CHEM. SOC., (20031203), vol. 125, no. 48, pages 14859 - 66 | - SIGURSKJOLD B.W., ANAL BIOCHEM., (20000115), vol. 277, no. 2, pages 260 - 6 | - NOCIARI, M. M; SHALEV, A.; BENIAS, P.; RUSSO, C., JOURNAL OF IMMUNOLOGICAL METHODS, (1998), vol. 213, pages 157 - 167 | - A. AVDEEF, "Physicochemical Profiling (Solubility, Permeability and Charge State", CURRENT TOPICS IN MEDICINAL CHEMISTRY, (2001), pages 277 - 351 | WO2006GB01382 |